{"schema_version":"secwatch.filing_event.v1","accession":"0001404644-24-000049","form_type":"8-K","ticker":"NGNE","cik":"0001404644","company_name":"Neurogene Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.268659+00:00","generated_at":"2026-06-02T17:21:29.633519+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Neurogene's NGN-401 gene therapy well tolerated in first three Rett syndrome patients; no overexpression toxicity","bullets":["All three pediatric patients (ages 4-7) treated with single ICV dose show mild, transient AEs; no serious adverse events.","No signs of MeCP2 overexpression toxicity in any patient, including one with a mild variant predicted to retain residual MeCP2 expression.","Follow-up ranges from ~3 to ~9 months; data cut-off April 19, 2024.","Interim efficacy data from Cohort 1 expected in Q4 2024; additional data including Cohort 2 in H2 2025.","NGN-401 uses EXACT transgene regulation technology to limit overexpression risk."],"urls":{"canonical":"https://secwatch.observer/filing/0001404644-24-000049","json":"https://secwatch.observer/filing/0001404644-24-000049.json","markdown":"https://secwatch.observer/filing/0001404644-24-000049.md","text":"https://secwatch.observer/filing/0001404644-24-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000049/0001404644-24-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000049/ngne-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T17:21:29.633519+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}